Skip to main content
Premium Trial:

Request an Annual Quote

XDx Licenses U. of Minnesota IP to Develop Lupus Dx

NEW YORK (GenomeWeb News) — XDx will in-license IP from the University of Minnesota that will enable the company to use gene expression technology to assess the status of systemic lupus erythematosus in patients, it said last week.
 
XDx also said it has entered a separate agreement with UM and the Feinstein Institute for Medical Research in New York that gives the company access to SLE patient samples taken from an NIH-funded study of biomarkers for autoimmune diseases.
 
The company plans to use these samples to in its work to develop lupus diagnostics.
 
Financial terms of the agreement were not released.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.